Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives
The landscape of cancer treatment is rapidly evolving with the emergence of promising novel therapies, offering new hope for patients with challenging malignancies. This review explores key advancements, including next-generation immunotherapies targeting novel biomarkers, innovative cell therapies,...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-06-01
|
| Series: | Medicine Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950347725000180 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423173936742400 |
|---|---|
| author | Huilei Miao Yuan Fang Chongxian Pan Hanshuo Yang Zhipeng Wang Ye Qi Yan Wu Ying Zhang Fangpeng Liu Huiyao Huang Yu Tang Dawei Wu Ning Li |
| author_facet | Huilei Miao Yuan Fang Chongxian Pan Hanshuo Yang Zhipeng Wang Ye Qi Yan Wu Ying Zhang Fangpeng Liu Huiyao Huang Yu Tang Dawei Wu Ning Li |
| author_sort | Huilei Miao |
| collection | DOAJ |
| description | The landscape of cancer treatment is rapidly evolving with the emergence of promising novel therapies, offering new hope for patients with challenging malignancies. This review explores key advancements, including next-generation immunotherapies targeting novel biomarkers, innovative cell therapies, personalized neoantigen-based treatments, gene therapies, and advanced drug delivery systems. Immunotherapies are expanding beyond traditional checkpoints, with new targets such as ITPRIPL1 and LILRBs showing promising potential to enhance antitumor immunity. Cell therapies beyond autologous chimeric antigen receptor-T (CAR-T), such as in vivo CAR-T, are advancing with improved manufacturing processes. Gene therapies, such as miRNA-targeting approaches and plant immune protein RDR1, offer new strategies for restoring gene expression. Additionally, mRNA-based therapies are gaining traction for their precision in delivering therapeutic agents, while novel drug delivery systems are improving treatment efficacy and specificity. These therapies, while promising, face challenges such as the early-stage nature of most trials, which limits conclusions about long-term efficacy and safety, the potential insufficiency of monotherapies targeting these pathways, and issues related to stability and cell permeability. Future research will focus on optimizing these therapies to maximize their clinical impact and explore synergistic combinations for enhanced efficacy. |
| format | Article |
| id | doaj-art-6c20d2cae5004e939a9a7a1dcbac90e7 |
| institution | Kabale University |
| issn | 2950-3477 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Medicine Plus |
| spelling | doaj-art-6c20d2cae5004e939a9a7a1dcbac90e72025-08-20T03:30:44ZengKeAi Communications Co., Ltd.Medicine Plus2950-34772025-06-012210008710.1016/j.medp.2025.100087Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectivesHuilei Miao0Yuan Fang1Chongxian Pan2Hanshuo Yang3Zhipeng Wang4Ye Qi5Yan Wu6Ying Zhang7Fangpeng Liu8Huiyao Huang9Yu Tang10Dawei Wu11Ning Li12Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medicine, Brigham and Women’s Hospital, Boston 02132, MA, USADepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, ChinaLikang Life Sciences Technology Co., Ltd., Beijing 100015, ChinaNeoevolution (Beijing) Medical Technology Co., Ltd., Beijing 102202, ChinaAbogen Biosciences, Suzhou Abogen Biosciences, Suzhou 215000, ChinaNuwacell Biotechnologies Co., Ltd., Hefei 230088, ChinaSugar Pharmaceutical Technology (Beijing) Co., Ltd., Beijing 102206, ChinaClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaClinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Corresponding authors.Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Corresponding authors.The landscape of cancer treatment is rapidly evolving with the emergence of promising novel therapies, offering new hope for patients with challenging malignancies. This review explores key advancements, including next-generation immunotherapies targeting novel biomarkers, innovative cell therapies, personalized neoantigen-based treatments, gene therapies, and advanced drug delivery systems. Immunotherapies are expanding beyond traditional checkpoints, with new targets such as ITPRIPL1 and LILRBs showing promising potential to enhance antitumor immunity. Cell therapies beyond autologous chimeric antigen receptor-T (CAR-T), such as in vivo CAR-T, are advancing with improved manufacturing processes. Gene therapies, such as miRNA-targeting approaches and plant immune protein RDR1, offer new strategies for restoring gene expression. Additionally, mRNA-based therapies are gaining traction for their precision in delivering therapeutic agents, while novel drug delivery systems are improving treatment efficacy and specificity. These therapies, while promising, face challenges such as the early-stage nature of most trials, which limits conclusions about long-term efficacy and safety, the potential insufficiency of monotherapies targeting these pathways, and issues related to stability and cell permeability. Future research will focus on optimizing these therapies to maximize their clinical impact and explore synergistic combinations for enhanced efficacy.http://www.sciencedirect.com/science/article/pii/S2950347725000180Cancer immunotherapyCell therapyGene therapyMRNA therapeuticsDrug delivery systems |
| spellingShingle | Huilei Miao Yuan Fang Chongxian Pan Hanshuo Yang Zhipeng Wang Ye Qi Yan Wu Ying Zhang Fangpeng Liu Huiyao Huang Yu Tang Dawei Wu Ning Li Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives Medicine Plus Cancer immunotherapy Cell therapy Gene therapy MRNA therapeutics Drug delivery systems |
| title | Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives |
| title_full | Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives |
| title_fullStr | Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives |
| title_full_unstemmed | Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives |
| title_short | Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives |
| title_sort | transforming the landscape of cancer treatment with seven promising novel therapies evolution and future perspectives |
| topic | Cancer immunotherapy Cell therapy Gene therapy MRNA therapeutics Drug delivery systems |
| url | http://www.sciencedirect.com/science/article/pii/S2950347725000180 |
| work_keys_str_mv | AT huileimiao transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT yuanfang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT chongxianpan transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT hanshuoyang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT zhipengwang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT yeqi transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT yanwu transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT yingzhang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT fangpengliu transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT huiyaohuang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT yutang transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT daweiwu transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives AT ningli transformingthelandscapeofcancertreatmentwithsevenpromisingnoveltherapiesevolutionandfutureperspectives |